Phaseline

Targets › PDCD7

PDCD7 (Programmed cell death protein 7): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Promotes apoptosis when overexpressed. (UniProt, Q8N8D1)

Open in Phaseline: the race on PDCD7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NextPoint TherapeuticsNPX372
B7-H7:CD3 bispecific antibody
PDCD7, CD3EPhase 1Metastatic Malignant NeoplasmApr 2027

Conditions

Metastatic Malignant Neoplasm (1)

Modalities

small molecule (1)

Companies

NextPoint Therapeutics (1)

Related targets

CD3E (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.